Search
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … [L6037] However, these stimulant medications are limited by dose-related side effects and concerns of abuse.
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … [A259961] Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds
Categories: Agents to Treat Airway DiseasePinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalAlthough it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. … It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable
Quinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigationalQuinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure. … [A184844] Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]
Categories: Agents Acting on the Renin-Angiotensin SystemNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Pipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnInterestingly, this drug has been studied for bactericidal properties, however, is not currently, used for this purpose [A32725]. … Experimentation with the drug and its derivatives for recreational purposes has led to many cases of acute toxicity and has been linked to three fatalities.